Jubilant Life Sciences Limited announced unaudited consolidated and stand-alone earnings results for the third quarter and nine months ended December 31, 2012. For the quarter on consolidated basis, the company reported total income from operations of INR 13,060 million against INR 10,950 million a year ago. EBITDA including other income was INR 2,630 million against INR 2,120 million a year ago. Profit after interest but before exceptional items was INR 1,460 million against INR 1,010 million a year ago. Net profit after tax and minority interest was INR 270 million or INR 1.68 per basic share against net loss after tax and minority interest of INR 780 million or INR 4.92 per basic share a year ago. Normalized net profit after tax was INR 980 million or INR 6.13 per basic share against INR 770 million or INR 4.84 per basic share a year ago.

For the nine months on consolidated basis, the company reported total income from operations of INR 31,690 million against INR 30,990 million a year ago. EBITDA including other income was INR 8,110 million against INR 6,450 million a year ago. Profit after interest but before exceptional items was INR 4,550 million against INR 3,390 million a year ago. Net profit after tax and minority interest was INR 1,840 million or INR 1.53 per basic share against INR 780 million or INR 4.90 per basic share a year ago. Normalized net profit after tax was INR 3,160 million or INR 19.85 per basic share against INR 2,800 million or INR 17.60 per basic share a year ago.

The company provided earnings guidance for fiscal year 2013. For the period, the company expects to achieve over 20% revenue growth with EBITDA margins sustainable at about 21% backed by new product launches and geographic expansion in Pharma products; higher utilization of capacities in Life Science Ingredients and CMO businesses, and continued efforts to improve global competitiveness through increased vertical integration, higher yields and realigned cost and revenue structure.

For the quarter on stand-alone basis, the company reported net sales/income from operations was INR 8,108.3 million against INR 6,778.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 910.9 million against INR 778.7 million a year ago. Loss from ordinary activities before tax was INR 192.6 million compared to INR 1,157.5 million for the same period a year ago. Net loss was INR 251.4 million or INR 1.58 diluted loss per share against INR 1,370.2 million or INR 8.60 diluted loss per share a year ago.

For nine months on stand-alone basis, the company reported net sales/income from operations was INR 22,841.9 million against INR 19,240.8 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 2,620 million against INR 2,565.6 million a year ago. Profit from ordinary activities before tax was INR 130.4 million compared to loss from ordinary activities before tax of INR 433.1 million for the same period a year ago. Net loss was INR 151.4 million or INR 0.95 diluted loss per share against INR 781.3 million or INR 4.91 diluted loss per share a year ago.